Orgenesis Inc. Free Cash Flow per Share

Free Cash Flow per Share of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow per Share growth rates and interactive chart. Free cash flow per share. Calculated as operating cash flow minus capital expenditures and divided by the weighted average number of shares outstanding. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. It is usually used in discounted cash flow models to determine a company's intrinsic value.


Highlights and Quick Summary

  • Free Cash Flow per Share for the quarter ending September 29, 2021 was -0.5 (a 2.27% increase compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow per Share decreased by -73.63%
  • Annual Free Cash Flow per Share for 2020 was -3.28 (a 134.94% increase from previous year)
  • Annual Free Cash Flow per Share for 2019 was -1.4 (a -2.43% decrease from previous year)
  • Annual Free Cash Flow per Share for 2018 was -1.43 (a -9.96% decrease from previous year)
  • Twelve month Free Cash Flow per Share ending September 29, 2021 was -3.09 (a 2.75% increase compared to previous quarter)
  • Twelve month trailing Free Cash Flow per Share decreased by -6.05% year-over-year
Trailing Free Cash Flow per Share for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-3.09 -3.01 -2.93 -3.29
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow per Share of Orgenesis Inc.

Most recent Free Cash Flow per Shareof ORGS including historical data for past 10 years.

Interactive Chart of Free Cash Flow per Share of Orgenesis Inc.

Orgenesis Inc. Free Cash Flow per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.5 -0.48 -0.24
2020 -1.88 -0.47 -0.44 -0.81 -3.28
2019 -0.55 -0.35 -0.34 -0.35 -1.4
2018 -0.44 -0.51 -0.52 -0.25 -1.43
2017 -0.18 -0.25 0.0 0.02 -0.35
2016 0.0 -0.15 0.0 -0.32 -0.39
2015 0.0 -0.79
2014 0.0 -0.32
2013 0.0 -0.47
2012 0.0 0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.